Clinical Impact of Down-Regulated Plasma miR-92a Levels in Non-Hodgkin's Lymphoma
2011

Plasma miR-92a Levels in Non-Hodgkin's Lymphoma

Sample size: 126 publication Evidence: moderate

Author Information

Author(s): Hyashiki Kazuma, Umezu Tomohiro, Yoshizawa Sei-ichiro, Ito Yoshikazu, Ohyashiki Michiyo, Kawashima Hisashi, Tanaka Masami, Kuroda Masahiko, Ohyashiki Junko H.

Primary Institution: Tokyo Medical University, Tokyo, Japan

Hypothesis

The study evaluates the clinical relevance of miR-92a in plasma obtained from non-Hodgkin's lymphoma patients.

Conclusion

Plasma miR-92a levels could serve as a novel biomarker for diagnosing and monitoring lymphoma patients after chemotherapy.

Supporting Evidence

  • Plasma miR-92a levels were significantly lower in NHL patients compared to healthy subjects.
  • Patients in complete remission with low miR-92a levels had a higher relapse rate.
  • The study used 144 specimens from NHL patients for statistical analysis.

Takeaway

This study found that low levels of a molecule called miR-92a in the blood can help doctors understand how lymphoma patients are doing and if they might relapse.

Methodology

The study involved analyzing plasma samples from NHL patients and comparing miR-92a levels to those of healthy controls using quantitative real-time PCR and microarray analysis.

Limitations

The study had a small sample size for some analyses, which may limit the generalizability of the findings.

Participant Demographics

Patients included 76 with diffuse large B-cell lymphoma, 32 with follicular lymphoma, and 18 with T-cell NHL.

Statistical Information

P-Value

p<0.0001

Confidence Interval

95% CI: 81.32% to 97.19%

Statistical Significance

p<0.0001

Digital Object Identifier (DOI)

10.1371/journal.pone.0016408

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication